secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001493152-26-009428
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine reports FY2025 net loss of $9.6M; cash $14.9M; PPD Phase 3 topline due April 2026
--------------------------------------------------------------------------------

- Net loss of $9.6M ($1.69/diluted) vs $8K net income in FY2024; revenue fell to $2.0M from $11.2M.
- Cash and equivalents $14.9M at Dec 31, 2025, increased to $24.7M post-ATM offering in Q1 2026.
- Phase 3 study of LPCN 1154 (PPD) completed last patient visit; topline data expected early April 2026.
- R&D expenses rose to $8.6M from $7.4M on higher clinical study costs; G&A down to $3.8M.
- Company plans 505(b)(2) NDA submission for LPCN 1154 in mid-2026 if Phase 3 successful.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226009428/0001493152-26-009428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226009428/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-009428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer